Sobi completes share issue and announces repurchase offer

Swedish Orphan Biovitrum AB (Sobi) has completed a directed issue of redeemable and convertible class C shares. The company's board of directors has been authorized to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all holders of these shares.

The resolution for the share issue and subsequent repurchase offer was made at the Annual General Meeting on May 6, 2026. Sobi announced on July 15, 2026, that its board had decided to proceed with the repurchase, conditional upon subscription and payment from Svenska Handelsbanken AB.

The purpose of these share arrangements is to secure Sobi's obligations under its outstanding agreements. The company has previously communicated that this is part of its broader financial strategy. Further details on the repurchase process and timeline are expected.

Sobi is a biopharmaceutical company focused on rare diseases. The company is listed on Nasdaq Stockholm.